Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jessica Hults

Optometrist Indianapolis, IN Doctor of Optometry

NPI 1598325763 CMS profile 6050844

9202 N Meridian St, Indianapolis, IN 46260

Open in the dashboard

General payments

$10,102

199 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,950 paid to institutions, not to them · program year 2022

Through program year 2025, Jessica Hults of Indianapolis, IN is reported in the CMS Open Payments database as having received $10,102 across 199 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $6,950 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,985 26
2024 General $1,911 29
2023 General $1,322 26
2022 General $1,080 38
2021 General $2,199 44
2020 General $432 18
2019 General $1,173 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Hults
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Jessica Hults were reported at $1,985. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Jessica Hults Optometrist median Middle half National median
2019 $1,173 $159 $67–$371 $163
2020 $432 $72 $29–$165 $114
2021 $2,199 $125 $46–$292 $132
2022 $1,080 $162 $66–$374 $149
2023 $1,322 $177 $72–$406 $160
2024 $1,911 $188 $77–$427 $164
2025 $1,985 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. RxSight Inc $3,947 33 payments
  2. Lensar, Inc. $1,094 14 payments
  3. Allergan Inc. $804 27 payments
  4. Alcon Vision LLC $563 19 payments
  5. Johnson & Johnson Surgical Vision, Inc. $513 6 payments
  6. Bausch & Lomb, a division of Bausch Health US, LLC $452 11 payments
  7. Bausch & Lomb Americas Inc. $451 14 payments
  8. Glaukos Corporation $413 8 payments
  9. Novartis Pharmaceuticals Corporation $388 21 payments
  10. AbbVie, Inc. $264 13 payments
  11. Other $1,213 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,820 190 payments
  2. Consulting Fee $3,000 7 payments
  3. Travel and Lodging $257 1 payment
  4. Honoraria $26 1 payment
Products named General payments · program years 2019–2025
  1. RXSIGHT LIGHT DELIVERY DEVICE (LDD) $3,314 25 payments
  2. RXSIGHT CONTACT LENS $3,314 25 payments
  3. RXSIGHT INJECTOR CARTRIDGE $3,314 25 payments
  4. RXSIGHT INJECTOR HANDPIECE $3,314 25 payments
  5. LIGHT ADJUSTABLE LENS (LAL) $2,566 18 payments
  6. LENSAR LASER SYSTEM $1,094 14 payments
  7. RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL) $748 7 payments
  8. LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD) $634 8 payments
  9. VYZULTA $560 17 payments
  10. XIIDRA $546 24 payments
  11. Other $5,868 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

462

Median for Optometry: 120

Drug cost

$127,492

Median for Optometry: $8,864

Branded share of claims

39.4%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 59 $66,118
Lumigan Bimatoprost Brand 47 $28,253
Combigan Brimonidine Tartrate/Timolol Brand 20 $8,918
Alphagan P Brimonidine Tartrate Brand 15 $7,475
Cyclosporine Generic 16 $6,031
Lotemax Sm Loteprednol Etabonate Brand 17 $4,220
Travoprost Generic 17 $2,087
Loteprednol Etabonate Generic 12 $1,544
Latanoprost Generic 153 $1,361
Prednisolone Acetate Generic 24 $967

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$35,673

Medicare's payments for the services billed

Medicare patients

270

Average age 76

Services billed

698

153 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 38%
Chronic kidney disease 29%
Ischemic heart disease 27%
Depression 24%
Atrial fibrillation 17%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OXERVATE
  • Dompe US, Inc. $150
$150 — —
Syfovre
  • Apellis Pharmaceuticals, Inc. $124
$124 — —
MIEBO
  • Bausch & Lomb Americas Inc. $72
$72 — —
XIIDRA
  • Bausch & Lomb Americas Inc. $72
$72 — —
LUMIGAN
  • AbbVie, Inc. $61
$61 47 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

199 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record